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CAPITOLO 4:    GLYCOCLUSTERS PER ARRAY DI DNA 
 
 
 
 
 
 
 
 
 
4.1 Introduction 
Many key physiological and pathological events occur through interactions between carbohydrate 
and sugar-binding proteins called lectins. The host-pathogen recognitions offer many examples of 
such interactions. For example, the first step of the infection of influenza virus involves the 
adhesion of the virion to sialic acid residues present onto the surface of endothelial cells mediated 
by the viral hemagglutinin. A similar approach is exploited by bacteria and parasites. 
Therefore, understanding the structure-function relationships of this molecular recognition 
process may provide access to innovative therapeutic strategies. Nevertheless, since natural 
carbohydrate-lectin interactions are usually weak, glycochemists have devoted many efforts in 
designing high affinity artificial ligands, including glycosides bearing hydrophobic aglycons1 and, 
more recently, glycoclusters,2 to take advantage of the so-called cluster effect.3-5 It is worth noting 
that, in the case of glycoclusters, the affinity is not only related to the multivalency.6 In fact, 
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different authors have demonstrated the importance of the spatial distribution of the glycoside 
residues for obtaining high affinities.7 
Calix[4]arenes can be synthesized in various blocked conformations, thus providing a series of 
well-defined geometries for the display of sugar ligands. A recent study demonstrated that N-
glycosylated calix[n]arenes of variable valencies and geometries are capable of distinguishing 
among lectins of a family.8 
We report herein the synthesis of C-glycosylated calix[4]arenes in which four galactose residues 
are linked through an alkyl triazole tether to the upper rim of the macrocycle cavity while an azido 
group is present on the opposite side. Next, the calixsugars were grafted through copper-mediated 
azide-alkyne cycloaddition (CuAAC) on mono or dipropargyloxymethyl-propanediol moieties 
allowing the synthesis of oligonucleotides bearing one or two calixarene glycoclusters, respectively. 
Finally, their affinity for lectins PA-IL9 and RCA 120, galactose specific lectins from Pseudomonas 
aeruginosa and Ricinus communis, respectively, were compared to that displayed by linear and 
antenna-type glycoclusters.10, 11 The evaluation of the affinity of each glycomimic was performed 
on a DNA-based glycoarray platform as previously described12 by direct fluorescence scanning and 
by determination of their IC50 values.13 
 
4.2 Synthesis of C-galactosyl calix[4]arene clusters 
We designed calix[4]arene based glycoclusters 1 and 2 (Figure 1) functionalized with a single 
azido group with the aim of introducing these multi-glycosylated molecules into oligonucleotides 
via the copper catalyzed azide-alkyne cycloaddition (click chemistry).14 The calix[4]arenes were 
chosen as platforms because they can be easily derivatized at both the upper (wide) and lower 
(narrow) rims and they are endowed with a well organized three-dimensional architecture.15 Among 
the four possible conformations (cone, partial cone, 1,2-alternate, 1,3-alternate) adopted by 
calix[4]arenes, the cone structure allows a spatially close arrangement of the four sugar ligands at 
one side of the macrocycle. 
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Figure 1. 
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The synthesis of densely substituted calix[4]arenes 1 and 2 is succinctly described. The key 
intermediate 7 was first targeted from the known16 tetra-allyl-calix[4]arene 3 via calixarene 
chemistry (Scheme 1). Compound 7 featured four azidopropyl groups at the upper rim and only one 
free hydroxy group at the lower rim, while the other three hydroxy groups were protected as O-
propyl ethers to insure a blocked cone conformation of the macrocycle. Unfortunately, the 
regioselective, direct protection of three phenolic hydroxy groups of calix[4]arene derivatives is a 
not trivial task. In fact, the synthesis of lower rim di-alkylated17 and tetra-alkylated18 calix[4]arenes 
in cone conformation is a straightforward transformation, whereas the preparation of the 
corresponding tri-alkyl ethers is troublesome and often requires multistep methods.19, 20 A well 
known procedure18, 21 for the synthesis of tri-O-alkylated calix[4]arenes involves the treatment of 
the tetra-hydroxy derivative with an excess of alkyl halides in the presence of BaO and Ba(OH)2. 
However, when the tetra-allyl-calix[4]arene 3 was submitted to these reaction conditions, both the 
di- and tri-propyl ethers were formed in low yield (ca. 25% each). Thus, the target tetra-azidated 
calixarene 7 was prepared starting from 3 employing an alternative strategy to differentiate one of 
the four hydroxy groups at the lower rim. Taking advantage of our previous studies on the synthesis 
of calix[4]arene based glycoclusters,22-25 3 was mono-glycosylated by reaction with commercially 
available α-D-mannofuranose diacetonide 4 (1.1 equiv.) under Mitsunobu conditions22 and then the 
three residual hydroxy groups were protected as O-propyl ethers to give compound 5 in 80% 
isolated yield (two steps). The first step of this new procedure afforded a mono-protected 
calix[4]arene in similar or even better yield than those registered exploiting previous methods based 
on the use of NaOMe20 (70-80%), LiOH26 (73-85%), K2CO327 (37-88%), CsF27 (60-85%), or 
(Bu3Sn)2O28 (47-80%) and very simple alkyl halides.29 
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Scheme 1 
With compound 5 in hand having all hydroxy groups suitably protected, the multiple 
hydroboration-oxidation of the four allyl groups at the upper rim was safely carried out to give  the 
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tetrol 6. Subsequent transformation by azidation with diphenyl phosphoryl azide and sodium azide 
followed by removal of the mannofuranose fragment by acidic hydrolysis afforded the tetra-azide 7. 
In order to obtain the glycocluster 1 featuring the azido group in close proximity of the macrocycle 
cavity, the free hydroxy group of 7 was alkylated with the short N-Boc ethylamino chain to give 8 
(Scheme 2). The fixed cone conformation of the calix[4]arene macrocycle adopted by 8 was 
supported by the presence in its 1H NMR spectrum of signals for the equatorial and axial protons of 
the methylene bridges as doublets at ca. 3.1 and 4.3 ppm, respectively. Then, click chemistry was 
performed on the tetra-azide 8 as described in earlier reports from our laboratory.24, 25 Accordingly, 
8 was allowed to react with a stoichiometric amount (4.0 equiv.) of known30 ethynyl 2,3,4,6-tetra-
O-acetyl-β-D-C-galactopyranoside 9 in the presence of CuI and Hünig’s base to give the triazole-
tethered tetravalent glycosylated calix[4]arene 10. Quite remarkably, the four click reactions on the 
same substrate 8 must have occurred quite efficiently as compound 10 was obtained in 75% yield, 
corresponding to a 93% average yield for each cycloaddition reaction. This good result is very 
likely due to the postulated25 complexation of a copper(I)-triazolide intermediate with the sugar 
alkyne, which is therefore placed in proximity of unreacted azido groups and can readily undergo an 
intramolecular cycloaddition. The regioisomeric assignment of the 1,4-disubstituted 1,2,3-triazole 
rings was established by 13C NMR spectroscopy as described in our earlier works.24 Removal of the 
N-Boc group from 10 under acidic conditions followed by a diazo-transfer reaction31 to convert the 
amino function into the azido group afforded 11. Finally, the latter compound was converted into 
the target calix[4]arene 1, bearing carbohydrate residues at the upper rim and a single azido group at 
the lower rim, by treatment with ammonia in methanol. 
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Scheme 2 
To obtain the glycocluster 2, displaying a long tether holding the azido group at the lower rim, 
the calix[4]arene derivative 7 was derivatized as the ethyl ester 12 (Scheme 3), which was 
submitted to the standard click reaction with the sugar alkyne 9 to give the glycocluster 13 in high 
yield (80%). Also in this case, the fixed cone conformation of the calix[4]arene scaffold and the 
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1,4-disubstitution pattern of the triazole rings were readily confirmed by 1H and 13C NMR analyses, 
respectively. Transesterification of 13 followed by basic hydrolysis, afforded the compound 14 
wherein not only the ester group at the lower rim of the macrocycle but also those of the sugar 
residues had been removed. Finally the azido group was introduced in 14 by N-(3-
dimethylaminopropyl)-N’-ethyl-carbodiimide (EDC) activated amidic coupling32 of the free 
carboxylic group with the commercially available 11-azido-3,6,9-trioxaundecan-1-amine 15 to give 
the target product 2. Compounds 1 and 2 were purified by reversed-phase column chromatography 
and characterized by NMR and MS analyses. 
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4.3 Synthesis and characterization of glycocluster-oligonucleotide hybrids. 
The assembly of glycoclusters 1 and 2 with oligonucleotide chains was carried out in order to 
immobilize the resulting glycoconjugates on a microarray surface. To this aim, oligonucleotides 
were prepared by a DNA synthesizer using the standard phosphoramidite chemistry33 on CPG 
(Controlled Pore Glass) solid support, a porous borosilicate material frequently used for DNA 
synthesis. Two different solid supported materials 1634 and 1735 (Scheme 4), displaying one and 
two alkyne residues respectively, were used for the synthesis of oligonucleotides 18 and 19 
displaying the same sequence (CTG CCT CTG GGT TCA)12 and labeled on the 5’-end with the 
fluorescent dye Cy3 (Scheme 4). Treatment of 18 and 19 with concentrated aqueous ammonia 
released the oligonucleotides from the solid support and removed the protecting groups (i.e. β-
cyanoethyl, benzoyl, and isobutyryl) (Scheme 4). The oligonucleotides 20 and 21 were isolated, 
their purity was established by analytical HPLC, and they were characterized by MALDI- TOF 
mass spectrometry.  
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Scheme 4. Solid-phase oligonucleotide synthesis (SPOS) of 5'-fluorescently labeled 
DNA 3'-mono- or di-alkynes: (1) 2.5% Cl2CHCO2H, CH2Cl2; (2) phosphoramidite 
derivative + benzylthiotetrazole; (3) Ac2O, N-methyl-imidazole, 2,6-lutidine; (4) 0.1 
M I2, THF-H2O-pyridine. The grey ball represents long chain alkyl CPG. B* = Abz, 
Cbz, Gibu or T and B = A, C, G or T. 
Since the alkyne-functionalized oligonucleotides 20 and 21 were water soluble compounds, we 
planned to carry out their coupling with azide functionalized glycoclusters 1 (Scheme 5) and 2 
(Scheme 6), respectively, in water using CuSO4 and sodium ascorbate as the source of copper(I). 
Both reactions were performed under microwave irradiation10 in order to achieve high reaction rates 
and therefore avoid some phosphodiester hydrolysis due to the presence of copper(I) ion.36 The 
crude products from the click reactions were purified by preparative HPLC and characterized by 
MALDI-TOF mass spectrometry to give the final glycoconjugates 22 and 23. 
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Scheme 6 
 
4.4 Preparation of DNA-based glycoarrays to probe lectin-carbohydrate interactions 
Our methodology12 for the surface immobilization of glycoconjugates on the microarrays was 
used as follows: a) construction of DNA chips, b) hybridization of the prepared glycocluster-
oligonucleotide conjugates bearing the complementary DNA sequence and the fluorescent dye Cy3, 
and c) addition of the fluorescently labeled lectins Cy5 or Alexa 647 (Figure 2). 
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Figure 2. Schematic representation of the method used to study lectin-carbohydrate interactions. 
 
Accordingly, first the 3’-amino-oligonucleotides (whose sequence was complementary to that of 
the glycoconjugates prepared) were covalently immobilized on functionalized37 52-well glass 
slides.38 Then, the glycocluster oligonucleotide derivatives 22 and 23, the previously tested12 
galactosyl conjugates 24a-d (Figure 3), and an additional galactosyl conjugate 25 bearing ten 
  
91 
galactose residues (Figure 4) were hybridized onto the chip in order to compare their lectin binding 
properties. Moreover, the tri-mannosyl conjugate 24e was immobilized as a negative control. 
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Figure 3. Structures of previously reported12 linear glycoconjugates 24a-e. 
 
Glycoconjugate 25 was synthesized as described for the synthesis of 24a-e, but in this case the 
alkyne functions were introduced using a dialkyne phosphoramidite derivative.11, 37 Thus, starting 
from universal solid support 1,3-propanediol, five dialkyne phosphoramidite derivatives were 
incorporated by phosphoramidite chemistry. The introduction of the ten galactose residues was 
performed by click chemistry assisted by microwaves10 and then the oligonucleotide was 
synthesized and labeled with a Cy3 phosphoramidite. The desired glycoconjugate 25 was obtained 
after ammonia treatment and HPLC purification. 
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Figure 4. Structure of the deca-galactose antenna glycoconjugate 25 prepared. 
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Scanning of the Cy3 fluorescence signal with the Microarray scanner GenePix 4100A displayed a 
homogeneous hybridization of all conjugates, except for 25, which included an oligonucleotide 
sequence different from that of the linear glycoconjugates 24a-e (Figure 5). Two different Cy3 
signals were observed for compound 24e (each value was the mean of four spots on the same row): 
for one row, the signal intensity was similar to that observed for the compounds 24a-d, whereas it 
was approximately one third for the other row. Further experiments confirmed that compound 24e 
hybridizes similarly to compounds 24a-d. 
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Figure 5. Fluorescence signals (a. u.) at 532 nm after hybridization monitoring the immobilization of 
glycoconjugates 22-25 on the DNA chip. 
Next, we studied the interaction of 22 and 23 with two different galactose-binding lectins: PA-IL9 
(Pseudomonas aeruginosa lectin) and RCA 120 (Ricinus communis agglutinin). PA-IL, the first 
Gram-negative bacterium Pseudomonas aeruginosa lectin isolated,39 features a narrow specificity 
spectrum for D-galactose containing molecules. This protein is constituted by four identical 
monomers in which four calcium-dependent binding sites are located. After hybridization, the 
Alexa 647-labeled PA-IL was deposited in each well at 2.8 µM concentration and, after incubation 
and washing of the glass slide with 0.02% Tween 20 in PBS solution, the chip was scanned at 532 
and 635 nm. The fluorescence signal of each conjugate was determined as the average of the mean 
fluorescence signal of four spots (Figure 6). The fluorescence image of Cy3 (Figure 6, left) proved 
that the glycoconjugates were still present after lectin incubation, while fluorescence image of 
Alexa 647 (Figure 6, right) was observed as a result of the binding of PA-IL. The selectivity of PA-
IL for the corresponding galactose derivatives 24a-d and 25 was demonstrated by the Alexa 647 
fluorescence signal at background level for mannose bearing glycoconjugate 24e (Figure 7). The 
relative affinity of PA-IL to the glycoconjugates can be directly monitored through the intensity of 
the lectin’s fluorescence signal.  
  
93 
As previously observed with RCA120,12 glycoconjugates exhibiting three galactose residues 
(24b and 24d) presented a better affinity for PA-IL than those with only one residue (24a and 24c) 
due to the expected cluster effect.4, 5 The nature of the linker (L1 and L2) between the galactose 
residues has little effect (24b vs. 24d). Surprisingly, lower affinities were observed when the 
number of galactose moieties was increased. Thus, the deca-galactosyl conjugate (25) displayed a 
two-fold decreased fluorescence signal while they were at background level for both 
glycoconjugates 22 and 23 as well as for the negative control 24e, thus indicating that 22 and 23 did 
not have affinity for PA-IL lectin (Figure 6-7). Actually, it was expected that PA-IL would strongly 
recognize 22 and 23 because they featured a triazole ring β-D-linked to the galactose moiety, a 
molecular motif closely related to phenyl β-D-galactoside, the most potent ligand for PA-IL. Two 
possible explanations for this finding can be advanced by considering that 1) steric hindrance can 
arise or 2) glycosylated calixarenes can sequester calcium ions, thus removing them from the 
binding site of the lectin. Hence, 1H NMR experiments were carried out to evaluate the 
complexation ability of glycoclusters 1 and 2 toward calcium(II) ions. The addition of anhydrous 
Ca(ClO4)2 to a solution of 1 in CD3OD led to an upfield shift (ca. 0.1 ppm) and broadening of the 
signals due to the four aromatic protons resonating at δ = 6.47-6.40 and to two (δ = 2.1) of the four 
upper rim benzyl-type methylene groups. Downfield shifts of other signals in the central part of the 
spectrum (δ = 4.5-3.7) were also observed. In a similar way, after treatment of glycocluster 2 with 
Ca(ClO4)2, its 1H NMR spectrum (in CD3OD) showed some changes. In particular, the signals of 
two (δ = 7.92) of the four H-5 triazole atoms were slightly shifted downfield whereas the signals of 
four aromatic protons (δ = 6.3) and four upper rim aliphatic protons (δ = 2.0) underwent a ca. 0.1 
ppm upfield shift. To confirm the cation selectivity of the recognition process, the same 
experiments were repeated replacing Ca(ClO4)2 with anhydrous NaClO4 in the CD3OD solutions. In 
this case, the spectra of 1 and 2 did not show any significant modification, suggesting that both 
glycoclusters can complex Ca2+ ions when installed onto the oligonucleotide chains and exposed to 
the lectin. This conclusion contrasted with the finding that no molecular recognition was detected 
even by increasing the amounts of calcium ions in the tris/HCl buffer used instead of phosphate 
buffer. Therefore, we conclude that the calcium sequestration cannot be taken as the causing effect 
for the lack of binding of 22 and 23 to PA-IL lectin. At this stage a convincing explanation for that 
observation is open to conjectures and may rather be related to steric hindrance. 
The present data showed that PA-IL recognizes more efficiently glycoclusters with linear spatial 
structure than those with antenna (25) and calixarene (22 and 23) structure. This result suggests that 
a too close proximity between the galactose moieties has a negative effect on the recognition by 
PA-IL. 
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Figure 6. Fluorescence images (a. u.) recorded after incubation of immobilized glycoconjugates 22-25 with 
Alexa 647-labeled PA-IL at 532 nm (left) and at 635 nm (right).  
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Figure 7. Fluorescence signals (a. u.) recorded at 635 nm after incubation of immobilized glycoconjugates 
22-25 with Alexa 647-labeled PA-IL.  
A similar affinity study was then performed employing RCA 120, another lectin recognizing 
galactose residues. RCA 12040 is a heterodimeric protein with a MW of 60 kDa, made up of two S-
S linked chains A and B, the latter containing two carbohydrate binding sites specific for galactose. 
Cy5-labeled RCA 120 was deposited in each well at 2 µM concentration and, after incubation and 
washing of the glass slide with 0.02% Tween 20 in PBS solution, it was scanned at 532 and 635 
nm. The fluorescence image of Cy3 (Figure 8, left) proved that the glycoconjugates were still 
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present after lectin incubation, while the fluorescence image of Cy5 (Figure 8, right) was observed 
as a result of the binding of RCA 120 with galactose residues. 
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Figure 8. Fluorescence images (a. u.) recorded at 532 nm (left) and 635 nm (right) after incubation of 
immobilized glycoconjugates 22, 23, 24b, 24e, and 25 with Cy5-labeled RCA 120. 
 
The fluorescence signal of each conjugate was determined as the average of the fluorescence 
signal of four spots. As expected, the Cy5 signal was at background level for the mannose bearing 
glycoconjugate 24e, highlighting the selectivity of RCA 120 for galactose (Figure 9).  
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Figure 9. Fluorescence signals (a. u.) at 635 nm after incubation with RCA 120. 
 
Interestingly and in contrast to the data obtained with PA-IL, we found that all galactosylated-
glycoconjugates were able to bind RCA 120. Therefore, in this case, the use of the non-natural 
calixarene scaffold and triazole linker did not prevent the molecular recognition of the sugar ligand 
by the lectin. The glycoconjugate 23, bearing eight galactose residues, displayed an affinity similar 
to that observed for 24b, the most active compound, featuring only three galactose moieties. The 
ratio of the intensities of the Cy5 signals for 23 and 22 was in the 1.2-2 range (from independent 
experiments) while the ratio of the galactose residues linked to these glycoconjugates was of 2. 
Surprisingly, RCA 120 bound with a lower affinity to compound 25 bearing ten residues in an 
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antenna spatial arrangement. These results indicate that the three-dimensional orientation of the 
sugar units is more important than their number. In fact 24b, bearing three galactose residues in a 
linear arrangement, was the most potent ligand among the seven glycoconjugates tested in the 
present study.  
 
In order to have a quantitative analysis of the binding affinities between lectin RCA 120 and 
glycoconjugates 22 and 23, the corresponding IC50 values were measured as previously reported41 
and compared with the IC50 values determined for 24a and 24b.13 We determined IC50 values as the 
concentration of lactose required for the removal of 50% of RCA 120 bound to the immobilized 
glycoconjugates. The glycoconjugates 22 or 23 were immobilized by hybridization at the bottom of 
the microwells and further incubated with mixtures of Cy5-labeled RCA 120 (2 µM) containing 
increasing concentrations of lactose (0.05 µM to 30 mM). Fluorescence images at 532 and 635 nm 
were then obtained after washing of the glass slides to remove the unbound lectins (Figure 10). 
Each experimental point is an average value of four spots. 
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Figure 10. Typical fluorescence images recorded after incubation with Cy5-labeled RCA 120 and 
increasing concentrations of lactose. 
 
The Cy5 fluorescence intensities were tabulated versus logarithmic lactose concentrations 
(Figure 11).  
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Figure 11. Competitive curves of Cy5-RCA120 with 22 immobilized on DNA chip in presence of an 
increasing concentration of lactose. Fluorescence intensity (a.u.) at 635 nm.  
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Figure 11. Competitive curves of Cy5-RCA120 with 23 immobilized on DNA chip in presence of an 
increasing concentration of lactose. Fluorescence intensity (a.u.) at 635 nm. 
The IC50 values for the mono-galactose 24a,13 the tri-galactose 24b,13 the tetra-galactose 22 and 
the octa-galactose 23 glycoconjugates are displayed in Table 1. 
Table 1. IC50 of glycoconjugates-RCA 120 binding. 
Glycoconjugate Valency IC50 µM Relative 
potency[a] 
Potency per 
galactose residue[b] 
24a 1 5.6±2.8[13] 1 1.0 
24b 3 385±45[13] 69 23 
22 4 114±14 20 5 
23 8 305±22 54 7 
[a] Calculated as the ratio of monomer glycoconjugate 24a to other 
glycoconjugates IC50 values. [b] Calculated as the ratio of relative potency to 
the number of galactose residues. 
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As expected, we found that the affinity of RCA 120 increased along with the number of galactose 
residues due to a higher local galactose concentration. IC50 measurements confirmed that RCA 120 
had affinity for compounds 24b and 23 in the same range. Moreover, the IC50 for 23 was 2.7 times 
higher than that for 22 leading to an affinity per residues increased by a factor of 1.3, whereas 
values in the 1.2-2 range were obtained when analyzed by fluorescence of Cy5 (Figure 9). 
Therefore, as already reported,5 the measured cluster effect depends on the assay conditions. 
 
4.5 Conclusion 
The present study showed that each class of galactose cluster (linear, calixarene and antenna) is 
recognized with different affinity by PA-IL and RCA 120 lectins. Our result showed that the spatial 
arrangement is more important than the number of galactose residues since the linear trivalent 
clusters (24b and 24d) were more able to bind lectins than antenna (25) and calixarene (22 and 23) 
ones exhibiting 10, 4 and 8 galactose moieties, respectively. Furthermore, we showed that PA-IL is 
more selective than RCA 120 since galactosyl-calixarene derivatives 22 and 23 were not recognized 
by PA-IL. The importance of spatial arrangement of the glycoside residues in the lectin recognition 
process has been assessed for the asialoglycoprotein receptor.12, 42, 43 It was showed that the 
trigalactose cluster with the higher distance between the sugar residues presents the optimal 
recognition.39, 42 
The recognition study was performed by direct fluorescence scanning and by the determination of 
the IC50 values, both techniques leading to similar results. 
The carbohydrate microarray used in this study required only minute amounts of material. The 
synthesis of the glycoconjugates could therefore be performed on a rather small scale but the 
miniaturization through the microarray technology provided the biological data for a complete 
study. 
 
4.6 Experimental Section 
All moisture-sensitive reactions were performed under a nitrogen atmosphere using oven-dried 
glassware. Anhydrous solvents were dried over standard drying agents44 and freshly distilled prior 
to use. Reactions were monitored by TLC on silica gel 60 F254 with detection by charring with 
sulfuric acid. Flash column chromatography45 was performed on silica gel 60 (40-63 µm). Melting 
points were determined with a capillary apparatus. Optical rotations were measured at 20 + 2 °C in 
the stated solvent; [α]D values are given in deg.mL.g-1.dm-1. 1H NMR (300 and 400 MHz) and 13C 
NMR spectra (75 and 100 MHz) were recorded from CDCl3 solutions at room temperature unless 
otherwise specified. Peak assignments were aided by 1H-1H COSY and gradient-HMQC 
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experiments. In the 1H NMR spectra reported below, the n and m values quoted in geminal or 
vicinal proton-proton coupling constants Jn,m refer to the number of the corresponding sugar 
protons. 
High performance liquid chromatography (HPLC) analyses and purifications were performed on a 
Waters-Millipore instrument equipped with a Rheodyne injector, a 600S controller and a model 996 
photodiode array detector. For analyses, a reverse phase C18 Nucleosil (5 µm) column (150 x 4.6 
mm; Macherey-Nagel, Germany) was used at a flow rate of 1 mL.min-1 using a linear gradient of 
acetonitrile 5% to 60% in 0.05 M aqueous triethylammonium acetate (pH 7) for 25 min. For 
purifications, a reverse phase C18 Delta-Pak (15 µm) column (7.8 x 300 mm; Waters, Japan) was 
used at a flow rate of 2 mL.min-1 using a linear gradient of acetonitrile 24% to 48% in 0.05 M 
aqueous triethylammonium acetate (pH 7) for 25 min. 
MALDI-TOF mass spectra were recorded on a Voyager mass spectrometer (Perspective 
Biosystems, Framingham, MA) equipped with a nitrogen laser. MALDI conditions: accelerating 
voltage 24 kV; guide wire 0.05% of the accelerating voltage; grid voltage 94% of the accelerating 
voltage; delay extraction time 500 ns. 1 µL of sample was mixed with 5 µL of a saturated solution 
of hydroxypicolinic acid (HPA) in acetonitrile-water (1:1, v/v) containing 10% of ammonium 
citrate, then a few beads of DOWEX 50W-X8 ammonium sulfonic acid resin were added. 1 µL of 
the above mixture was placed on a plate and dried at room temperature and pressure. 
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5,11,17,23-Tetraallyl-25-(2,3:5,6-di-O-isopropylidene-β-D-mannofuranosyl)-26,27,28-
tripropoxy-calix[4]arene (5). 
O O OO O
O O
O
O
 
 To a stirred solution of tetrol 3 (500 mg, 0.86 mmol) and triphenylphosphine (335 mg, 1.28 
mmol) in anhydrous toluene (10 mL) was added diisopropyl azodicarboxylate (250 µL, 1.28 mmol) 
and, after 15 min, hemiacetal 4 (243 mg, 0.94 mmol). Stirring was continued for an additional 1.5 h, 
then the mixture was concentrated. To a stirred solution of the residue in DMF (20 mL) was added 
NaH (0.30 g, 7.7 mmol, of a 60% dispersion in oil) and, after 10 min, 1-iodopropane (0.75 mL, 7.7 
mmol). The mixture was stirred at room temperature for 1.5 h, then diluted with CH3OH (0.5 mL) 
and, after 30 min, diluted with 1 M phosphate buffer at pH 7 (80 mL) and extracted with Et2O (2 x 
100 mL). The combined organic phases were dried (Na2SO4) and concentrated. The residue was 
eluted from a column of silica gel with CH2Cl2-cyclohexane (from 1:1 to 3:1) to give 5 (652 mg, 
80%) as a syrup; [α]D = -19.2 (c 0.6, CHCl3). 1H NMR (400 MHz): δ 6.98-6.92 (m, 4H, Ar), 6.08 
(ddt, 2H, J = 6.0, 12.0, 16.5 Hz, 2 CH2=CHCH2), 6.05-5.96 (m, 4H, Ar), 5.59-5.48 (m, 2H, 2 
CH2=CHCH2), 5.12-5.01 (m, 4H, 2 CH2=CHCH2), 4.87-4.75 (m, 4H, 2 CH2=CHCH2), 4.78 (dd, 
1H, J1,2 = 3.0, J2,3 = 6.3 Hz, H-2), 4.71 (dd, 1H, J3,4 = 4.0 Hz, H-3), 4.69 (d, 1H, H-1), 4.63 and 3.01 
(2d, 2H, J = 13.8 Hz, ArCH2Ar), 4.48-4.43 (m, 1H, H-5), 4.42 (d, 1H, J = 13.0 Hz, Hax of 
ArCH2Ar), 4.40 (d, 1H, J = 13.0 Hz, Hax of ArCH2Ar), 4.35 (d, 1H, J = 13.0 Hz, Hax of ArCH2Ar), 
4.23 and 3.88 (2dt, 2H, J = 5.5, 11.3 Hz, CH3CH2CH2O), 4.14-3.97 (m, 4H, 2 H-6, CH3CH2CH2O), 
3.65-3.57 (m, 2H, CH3CH2CH2O), 3.42-3.36 (m, 5H, H-4, 2 CH2=CHCH2), 3.08 (d, 1H, J = 13.0 
Hz, Heq of ArCH2Ar), 3.07 (d, 1H, J = 13.0 Hz, Heq of ArCH2Ar), 3.05 (d, 1H, J = 13.0 Hz, Heq of 
ArCH2Ar), 2.77-2.72 (m, 4H, 2 CH2=CHCH2), 2.12-1.98 (m, 4H, 2 CH3CH2CH2O), 1.94-1.82 (m, 
2H, CH3CH2CH2O), 1.60, 1.44, 1.39 (3s, 12H, 4 Me), 1.10 (t, 3H, J = 7.0 Hz, CH3CH2CH2O), 0.87 
(t, 6H, J = 7.0 Hz, 2 CH3CH2CH2O). 13C NMR (75 MHz): δ 156.2 (C), 156.1 (C), 153.6 (C), 152.4 
(C), 138.75 (CH), 138.66 (CH), 138.0 (CH), 137.8 (CH), 137.1 (C), 136.9 (C), 136.8 (C), 136.3 (C), 
134.0 (C), 133.8 (C), 132.9 (C), 132.7 (C), 131.8 (C), 129.4 (CH), 129.0 (CH), 127.3 (CH), 127.1 
(CH), 115.0 (CH2), 114.9 (CH2), 114.8 (CH2), 114.6 (CH2), 112.9 (C), 109.0 (C), 106.6 (CH), 79.1 
(CH), 78.9 (CH), 76.2 (CH), 73.3 (CH), 77.1 (CH2), 76.5 (CH2), 76.4 (CH2), 66.6 (CH2), 39.5 
(CH2), 39.35 (CH2), 39.30 (CH2), 31.7 (CH2), 31.0 (CH2), 30.9 (CH2), 26.9 (CH3), 26.1 (CH3), 25.5 
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(CH3), 24.7 (CH3), 23.5 (CH2), 22.7 (CH2), 10.8 (CH3), 10.1 (CH3), 9.7 (CH3). ESI MS (953.25): 
971.7 (M + NH4+).  
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5,11,17,23-Tetrakis(3-hydroxypropyl)-25-(2,3:5,6-di-O-isopropylidene-β-D-mannofuranosyl)-
26,27,28-tripropoxy-calix[4]arene (6). 
OO O
HO HO OHOH
OO
O O
O
O
 
To a cooled (0 °C), stirred solution of 5 (950 mg, 1.00 mmol) in anhydrous THF (10 mL) was 
added dropwise 9-boracyclo[3.3.1]nonane (32 mL, 16.0 mmol, of a 0.5 M solution in hexane). The 
solution was allowed to reach room temperature in 3 h, then cooled to 0 °C and slowly diluted with 
10 M NaOH (1 mL) and 35% H2O2 (3 mL). The mixture was stirred at room temperature for 15 min 
and then warmed to 60 °C. Stirring was continued for an additional 2 h, then the mixture was 
cooled to room temperature, diluted with 1 M phosphate buffer at pH 7 (80 mL), concentrated to 
remove the organic solvents, and extracted with AcOEt (2 x 100 mL). The combined organic phases 
were dried (Na2SO4) and concentrated. The residue was eluted from a column of Sephadex LH 20 
with 1:1 CH2Cl2-MeOH to give 6 (840 mg, 82%) as a white solid. An analytical sample was 
obtained by preparative TLC (silica gel 60, 0.5 mm, 10:1 CHCl3-CH3OH); [α]D = -15.6 (c 0.3, 
CHCl3). 1H NMR (300 MHz): δ 7.01-6.95 (m, 4H, Ar), 6.18-6.07 (m, 4H, Ar), 4.82 (dd, 1H, J1,2 = 
3.0, J2,3 = 5.6 Hz, H-2), 4.73 (dd, 1H, J3,4 = 3.9 Hz, H-3), 4.71 (d, 1H, H-1), 4.66 and 3.03 (2d, 2H, 
J = 13.5 Hz, ArCH2Ar), 4.50-4.45 (m, 1H, H-5), 4.46 (d, 1H, J = 13.0 Hz, Hax of ArCH2Ar), 4.43 
(d, 1H, J = 13.0 Hz, Hax of ArCH2Ar), 4.38 (d, 1H, J = 13.0 Hz, Hax of ArCH2Ar), 4.26 and 3.89 
(2dt, 2H, J = 5.9, 11.0 Hz, CH3CH2CH2O), 4.16-3.98 (m, 4H, 2 H-6, CH3CH2CH2O), 3.64 (t, 6H, J 
= 7.0 Hz, CH3CH2CH2O, 2 CH2CH2CH2OH), 3.49 (t, 4H, J = 7.0 Hz, 2 CH2CH2CH2OH), 3.42 (dd, 
1H, J4,5 = 6.8 Hz, H-4), 3.10 (d, 1H, J = 13.0 Hz, Heq of ArCH2Ar), 3.09 (d, 1H, J = 13.0 Hz, Heq of 
ArCH2Ar), 3.07 (d, 1H, J = 13.0 Hz, Heq of ArCH2Ar), 2.72 (t, 4H, J = 6.5 Hz, 2 CH2CH2CH2OH), 
2.19-1.98 (m, 16H, 4 CH2CH2CH2OH, 2 CH2CH2CH2OH, 2 CH3CH2CH2O), 1.90 (tq, 2H, J = 7.0, 
7.0 Hz, CH3CH2CH2O), 1.60, 1.42, 1.40 (3s, 12H, 4 Me), 1.09 (t, 3H, J = 7.0 Hz, CH3CH2CH2O), 
0.89 (t, 6H, J = 7.0 Hz, 2 CH3CH2CH2O). 13C NMR (75 MHz): δ 155.9 (C), 155.8 (C), 153.2 (C), 
152.0 (C), 137.1 (C), 137.0 (C), 136.8 (CH), 136.3 (C), 135.8 (C), 134.8 (C), 134.6 (C), 133.8 (C), 
132.7 (C), 132.5 (C), 131.6 (C), 129.0 (CH), 128.7 (CH), 127.0 (CH), 126.9 (CH), 126.8 (CH), 
112.8 (C), 109.0 (C), 106.7 (CH), 79.1 (CH), 78.9 (CH), 77.4 (CH2), 76.9 (CH2), 76.5 (CH2), 76.1 
(CH), 73.3 (CH), 66.6 (CH2), 62.45 (CH2), 62.39 (CH2), 62.2 (CH2), 62.1 (CH2), 34.2 (CH2), 33.64 
(CH2), 33.57 (CH2), 31.6 (CH2), 31.1 (CH2), 30.8 (CH2), 26.9 (CH3), 26.1 (CH3), 25.5 (CH3), 24.6 
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(CH3), 23.5 (CH2), 22.7 (CH2), 10.8 (CH3), 10.2 (CH3), 9.8 (CH3). ESI MS (1025.33): 1048.2 (M + 
Na+).  
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5,11,17,23-Tetrakis(3-azidopropyl)-25-hydroxy-26,27,28-tripropoxy-calix[4]arene (7). 
HO OO O
N3 N3 N3
N3
 
A mixture of calixarene tetrol 6 (774 mg, 0.76 mmol), sodium azide (390 mg, 6.00 mmol), 
diphenyl phosphoryl azide (980 µL, 4.53 mmol), 1,8-diazabicyclo[5.4.0.]undec-7-ene (450 µL, 3.02 
mmol), and anhydrous DMF (4 mL) was stirred at 110 °C for 16 h then cooled to room temperature, 
diluted with Et2O (100 mL), washed with H2O (20 mL), dried (Na2SO4), and concentrated. A 
solution of the residue in 2:1 CH2Cl2-CF3CO2H (6 mL) was kept at room temperature for 3 h, then 
concentrated. The residue was eluted from a column of silica gel with 2:1 CH2Cl2-cyclohexane to 
give 7 (397 mg, 60%) as a syrup. 1H NMR (300 MHz): δ 6.99 (s, 2H, Ar), 6.90 (s, 2H, Ar), 6.25-
6.20 (m, 4H, Ar), 4.84 (s, 1H, OH), 4.38 and 3.36 (2d, 4H, J = 13.0 Hz, 2 ArCH2Ar), 4.35 and 3.24 
(2d, 4H, J = 13.6 Hz, 2 ArCH2Ar), 3.86-3.80 (m, 2H, CH3CH2CH2O), 3.73 (t, 4H, J = 7.0 Hz, 2 
CH3CH2CH2O), 3.33 (t, 2H, J = 7.0 Hz, CH2CH2CH2N3), 3.30 (t, 2H, J = 7.0 Hz, CH2CH2CH2N3), 
2.96 (t, 4H, J = 6.8 Hz, 2 CH2CH2CH2N3), 2.75 (t, 2H, J = 7.0 Hz, CH2CH2CH2N3), 2.68 (t, 2H, J = 
7.0 Hz, CH2CH2CH2N3), 2.37-2.24 (m, 2H, CH3CH2CH2O), 2.14 (t, 4H, J = 7.5 Hz, 2 
CH2CH2CH2N3), 2.04-1.82 (m, 12H, 2 CH2CH2CH2N3, 2 CH3CH2CH2O), 1.45 (tt, 4H, J = 7.0, 7.0 
Hz, 2 CH2CH2CH2N3), 1.13 (t, 6H, J = 7.5 Hz, 2 CH3CH2CH2O), 0.94 (t, 3H, J = 7.5 Hz, 
CH3CH2CH2O). 13C NMR (75 MHz): δ 154.9 (C), 152.8 (C), 151.4 (C), 136.8 (C), 135.1 (C), 134.8 
(C), 133.2 (C), 132.6 (C), 131.2 (C), 130.7(C), 129.0 (CH), 128.3 (CH), 127.7 (CH), 127.6 (CH), 
77.6 (CH2), 76.6 (CH2), 50.6 (CH2), 50.3 (CH2), 32.1 (CH2), 31.9 (CH2), 31.8 (CH2), 30.8 (CH2), 
30.7 (CH2), 30.5 (CH2), 30.4 (CH2), 23.4 (CH2), 22.2 (CH2), 10.8 (CH3), 9.5 (CH3). ESI MS 
(883.10): 901.4 (M + NH4+). 
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5,11,17,23-Tetrakis(3-azidopropyl)-25-(2-t-butoxycarbonyl-aminoethoxy)-26,27,28-
tripropoxy-calix[4]arene (8). 
O OO O
BocHN
N3 N3
N3N3
 
To a stirred solution of alcohol 7 (110 mg, 0.12 mmol) in anhydrous DMF (2 mL) was added NaH 
(15 mg, 0.37 mmol, of a 60% dispersion in oil) and, after 15 min, 1-bromo-2-t-
butoxycarbonylaminoethane (84 mg, 0.38 mmol). The mixture was stirred at 50 °C for 18 h, then 
cooled to room temperature, diluted with 1 M phosphate buffer at pH 7 (15 mL) and extracted with 
Et2O (2 x 50 mL). The combined organic phases were dried (Na2SO4) and concentrated. The 
residue was eluted from a column of silica gel with 1:1 CH2Cl2-cyclohexane (containing 0.3% of 
Et3N) to give 8 (64 mg, 50%) as a syrup; 1H NMR (400 MHz): δ 6.98 (bt, 1H, J = 6.0 Hz, NH), 
6.85 (s, 4H, Ar), 6.08 (s, 2H, Ar), 6.05 (s, 2H, Ar), 4.40 and 3.06 (2d, 4H, J = 12.8 Hz, 2 ArCH2Ar), 
4.25 and 3.09 (2d, 4H, J = 13.2 Hz, 2 ArCH2Ar), 3.99 (t, 2H, J = 4.5 Hz, OCH2CH2N), 3.98-3.92 
(m, 2H, CH3CH2CH2O), 3.86-3.79 (m, 2H, CH3CH2CH2O), 3.77-3.71 (m, 2H, CH3CH2CH2O), 3.64 
(dt, 2H, J = 4.5, 6.0 Hz, OCH2CH2N), 3.28 (t, 4H, J = 6.8 Hz, 2 CH2CH2CH2N3), 3.04 (t, 4H, J = 
7.2 Hz, 2 CH2CH2CH2N3), 2.67 (t, 4H, J = 6.8 Hz, 2 CH2CH2CH2N3), 2.07 (t, 4H, J = 7.2 Hz, 2 
CH2CH2CH2N3), 1.93 (tt, 4H, J = 6.8, 6.8 Hz, 2 CH2CH2CH2N3), 1.87-1.76 (m, 6H, 3 
CH3CH2CH2O), 1.52 (s, 9H, t-Bu), 1.47 (tt, 4H, J = 7.2, 7.2 Hz, 2 CH2CH2CH2N3), 0.94 (t, 6H, J = 
7.5 Hz, 2 CH3CH2CH2O), 0.86 (t, 3H, J = 7.5 Hz, CH3CH2CH2O). 13C NMR (75 MHz): δ 156.5 
(C), 155.3 (C), 154.9 (C), 153.1 (C), 136.3 (C), 136.2 (C), 134.8 (C), 134.1 (C), 133.9 (C), 133.2 
(C), 133.0 (C), 129.0 (CH), 128.7 (CH), 127.6 (CH), 127.4 (CH), 78.9 (C), 77.2 (CH2), 76.5 (CH2), 
75.2 (CH2), 50.6 (CH2), 50.5 (CH2), 41.0 (CH2), 32.0 (CH2), 31.0 (CH2), 30.9 (CH2), 30.6 (CH2), 
30.4 (CH2), 28.7 (CH3), 22.7 (CH2), 22.5 (CH2), 10.2 (CH3). ESI MS (1026.28): 1044.7 (M + 
NH4+). 
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5,11,17,23-Tetrakis{3-[4-(2,3,4,6-tetra-O-acetyl-β-D-galacto-pyranosyl)-1H-1,2,3-triazol-1-
yl]propyl}-25-(2-t-butoxycarbonyl-aminoethoxy)-26,27,28-tripropoxy-calix[4]arene (10). 
O OO O
BocHN
O
AcO
AcO
OAc
OAc
N
N
N
O
AcO
AcO
OAc
OAc
N
N
N
N
N
N
N
N
N
OAcO
AcO
OAc
O
AcO
AcO OAc
AcO
AcO
 
A mixture of calix[4]arene tetra-azide 8 (34 mg, 0.03 mmol), ethynyl C-galactoside 9 (47 mg, 
0.12 mmol), freshly distilled N,N-diisopropylethylamine (105 µL, 0.60 mmol), CuI (6 mg, 0.03 
mmol), and anhydrous toluene (1 mL) was stirred in the dark at room temperature for 18 h, then 
concentrated. The residue was eluted from a column of silica gel with AcOEt (containing 0.3% of 
Et3N) to give 10 (55 mg, 75%), a white foam; [α]D = -8.8 (c 0.7, CHCl3). 1H NMR (400 MHz): δ 
7.72 (s, 1H, H-5 Tr.), 7.71 (s, 1H, H-5 Tr.), 7.58 (s, 2H, 2 H-5 Tr.), 6.90 (bt, 1H, J = 5.5 Hz, NH), 
6.84 (s, 4H, Ar), 6.07 (s, 2H, Ar), 6.04 (s, 2H, Ar), 5.53-5.51 (4dd, 4H, 4 H-4), 5.47-5.38 (4dd, 4H, 
4 H-2), 5.21-5.17 (4dd, 4H, 4 H-3), 4.76 (d, 2H, J1,2 = 10.0 Hz, 2 H-1), 4.72 (d, 2H, J1,2 = 10.0 Hz, 
2 H-1), 4.40 and 3.07 (2d, 4H, J = 13.2 Hz, 2 ArCH2Ar), 4.36-4.30 (4ddd, 4H, 4 H-5), 4.27 and 
3.09 (2d, 4H, J = 13.2 Hz, 2 ArCH2Ar), 4.14-4.07 (m, 16H, 8 H-6, 4 ArCH2CH2CH2), 4.01-4.00 (m, 
2H, OCH2CH2N), 3.97-3.93 (m, 2H, CH3CH2CH2O), 3.85-3.81 (m, 2H, CH3CH2CH2O), 3.76-3.72 
(m, 2H, CH3CH2CH2O), 3.63-3.60 (m, 2H, OCH2CH2N), 2.63-2.58 (m, 4H, 2 ArCH2CH2CH2), 
2.24-2.19 (m, 4H, 2 ArCH2CH2CH2), 2.17, 2.16, 2.03, 2.02, 1.99, 1.91, and 1.88 (7s, 48H, 16 Ac), 
2.04-1.85 (m, 8H, 4 ArCH2CH2CH2), 1.85-1.74 (m, 6H, 3 CH3CH2CH2O), 1.52 (s, 9H, t-Bu), 0.95 
(t, 6H, J = 7.5 Hz, 2 CH3CH2CH2O), 0.86 (t, 3H, J = 7.5 Hz, CH3CH2CH2O). 13C NMR (75 MHz): 
δ 170.4 (C), 170.1 (C), 170.0 (C), 169.7 (C), 169.6 (C), 156.4 (C), 155.3 (C), 155.1 (C), 153.3 (C), 
144.4 (C), 144.1 (C), 136.3 (C), 136.2 (C), 134.0 (C), 133.4 (C), 133.1 (C), 129.0 (CH), 128.9 
(CH), 128.7 (CH), 128.6 (CH), 128.4 (CH), 128.3 (CH), 128.2 (CH), 127.7 (CH), 127.6 (CH), 
127.3 (CH), 122.1 (CH), 78.9 (C), 77.5 (CH2), 76.7 (CH2), 75.2 (CH2), 74.7 (CH), 73.7 (CH), 71.8 
(CH), 68.7 (CH), 67.6 (CH), 61.5 (CH2), 49.7 (CH2), 49.5 (CH2), 40.9 (CH2), 31.8 (CH2), 31.0 
(CH2), 28.6 (CH3), 22.7 (CH2), 20.65 (CH3), 20.57 (CH3), 10.2 (CH3). ESI MS (2451.58): 1227.4 
(M + 2H+)/2. 
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5,11,17,23-Tetrakis{3-[4-(2,3,4,6-tetra-O-acetyl-β-D-galacto-pyranosyl)-1H-1,2,3-triazol-1-
yl]propyl}-25-(2-azidoethoxy)-26,27,28-tripropoxy-calix[4]arene (11). 
O OO O
N3
O
AcO
AcO
OAc
OAc
N
N
N
O
AcO
AcO
OAc
OAc
N
N
N
N
N
N
N
N
N
OAcO
AcO
OAc
O
AcO
AcO OAc
AcO
AcO
 
A solution of 10 (196 mg, 0.08 mmol) in CH2Cl2 (8 mL) and CF3CO2H (4 mL) was kept at room 
temperature for 1 h, then concentrated. To a mixture of the crude ammonium salt, K2CO3 (60 mg, 
0.44 mmol), CuSO4.5H2O (2 mg, 8 µmol), CH3OH (4 mL), and CH3CN (1 mL), was added 
imidazole-1-sulfonyl azide hydrochloride29 (40 mg, 0.20 mmol). The mixture was stirred at room 
temperature for 6 h, then concentrated, diluted with acetic anhydride (2 mL) and pyridine (2 mL), 
stirred for an additional 3 h, and concentrated. The residue was diluted with H2O (10 mL) and 
extracted with AcOEt (2 x 50 mL). The combined organic phases were dried (Na2SO4) and 
concentrated. The residue was eluted from a column of silica gel with AcOEt to give 11 (132 mg, 
69%) as a white foam; [α]D = -10.2 (c 0.7, CHCl3). 1H NMR (400 MHz): δ 7.69 (s, 1H, H-5 Tr.), 
7.67 (s, 1H, H-5 Tr.), 7.59 (s, 2H, 2 H-5 Tr.), 6.71 (s, 4H, Ar), 6.22 (s, 2H, Ar), 6.17 (s, 2H, Ar), 
5.54-5.51 (4dd, 4H, 4 H-4), 5.44 (dd, 2H, J1,2 = J2,3 = 10.0 Hz, 2 H-2), 5.42 (dd, 2H, J1,2 = J2,3 = 
10.0 Hz, 2 H-2), 5.22-5.16 (4dd, 4H, 4 H-3), 4.76 (d, 2H, 2 H-1), 4.73 (d, 2H, 2 H-1), 4.40 and 3.07 
(2d, 4H, J = 13.1 Hz, 2 ArCH2Ar), 4.34 and 3.10 (2d, 4H, J = 13.1 Hz, 2 ArCH2Ar), 4.32-4.25 (m, 
4H, 2 ArCH2CH2CH2), 4.18-4.07 (m, 18H, 4 H-5, 8 H-6, 2 ArCH2CH2CH2, OCH2CH2N3), 3.92-
3.86 (m, 4H, OCH2CH2N3, CH3CH2CH2O), 3.78-3.69 (m, 4H, 2 CH3CH2CH2O), 2.53-2.47 (m, 4H, 
2 ArCH2CH2CH2), 2.17, 2.16, 2.03, 2.02, 1.99, 1.90, and 1.88 (7s, 48H, 16 Ac), 2.18-2.08 (m, 8H, 2 
ArCH2CH2CH2, 2 ArCH2CH2CH2), 1.94-1.84 (m, 10H, 2 ArCH2CH2CH2, 3 CH3CH2CH2O), 1.04 
(t, 6H, J = 7.4 Hz, 2 CH3CH2CH2O), 0.94 (t, 3H, J = 7.4 Hz, CH3CH2CH2O). 13C NMR (75 MHz): 
δ 170.4 (C), 170.1 (C), 170.0 (C), 169.7 (C), 155.6 (C), 155.0 (C), 154.1 (C), 144.4 (C), 144.2 (C), 
135.8 (C), 135.6 (C), 134.0 (C), 133.8 (C), 133.6 (C), 133.4 (C), 128.5 (CH), 127.8 (CH), 127.5 
(CH), 122.1 (CH), 77.2 (CH2), 76.5 (CH2), 74.7 (CH), 73.8 (CH), 71.9 (CH), 71.3 (CH2), 68.6 
(CH), 67.6 (CH), 61.5 (CH2), 50.7 (CH2), 49.7 (CH2), 49.6 (CH2), 31.9 (CH2), 30.9 (CH2), 30.8 
(CH2), 29.6 (CH2), 23.3 (CH2), 23.0 (CH2), 20.7 (CH3), 20.6 (CH3), 10.5 (CH3), 10.0 (CH3). ESI 
MS (2377.46): 1189.7 (M + 2H+)/2; 1200.7 (M + Na+ + H+)/2. 
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5,11,17,23-Tetrakis{3-[4-(β-D-galactopyranosyl)-1H-1,2,3-triazol-1-yl]propyl}-25-(2-
azidoethoxy)-26,27,28-tripropoxy-calix[4]arene (1). 
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A solution of 11 (15 mg, 0.006 mmol) in a 2 M solution of NH3 in CH3OH (1 mL) was kept at 
room temperature for 16 h, then concentrated. The residue was eluted from a C18 silica gel 
cartridge with H2O-CH3OH (from 1:1 to 1:5), then CH3OH, to give 1 (9.7 mg, 90%) as an 
amorphous solid; [α]D = +14.2 (c 0.4, CH3OH). 1H NMR (400 MHz, CD3OD): δ 8.06, 8.03, 7.92, 
and 7.91 (4s, 4H, 4 H-5 Tr.), 6.79 (s, 4H, Ar), 6.47-6.45 (m, 2H, Ar), 6.40 (bs, 2H, Ar), 4.44 and 
3.12 (2d, 4H, J = 12.7 Hz, 2 ArCH2Ar), 4.39-4.34 (3d, 4H, 4 H-1), 4.37 and 3.14 (2d, 4H, J = 12.8 
Hz, 2 ArCH2Ar), 4.19 (t, 4H, J = 7.3 Hz, 2 ArCH2CH2CH2), 4.10-4.05 (m, 6H, 2 ArCH2CH2CH2, 
OCH2CH2N3), 3.99-3.87 (m, 12H, 4 H-4, 4 H-2, CH3CH2CH2O, OCH2CH2N3), 3.79-3.64 (m, 16H, 
4 H-5, 8 H-6, 2 CH3CH2CH2O), 3.64-3.59 (3d, 4H, J2,3 = 9.5, J3,4 = 3.2 Hz, 4 H-3), 2.42-2.36 (m, 
4H, 2 ArCH2CH2CH2), 2.11-2.04 (m, 8H, 2 ArCH2CH2CH2, 2 ArCH2CH2CH2), 2.02-1.90 (m, 6H, 3 
CH3CH2CH2O), 1.84-1.76 (m, 4H, 2 ArCH2CH2CH2), 1.08 (t, 6H, J = 7.5 Hz, 2 CH3CH2CH2O), 
1.00 (t, 3H, J = 7.5 Hz, CH3CH2CH2O). 13C NMR (75 MHz, CD3OD): δ 155.3 (C), 147.5 (C), 136.7 
(C), 135.3 (C), 130.0 (CH), 129.3 (CH), 124.9 (CH), 80.9 (CH), 78.3 (CH2), 76.3 (CH), 72.1 (CH), 
71.0 (CH), 62.9 (CH2), 52.2 (CH2), 50.3 (CH2), 33.0 (CH2), 31.7 (CH2), 24.6 (CH2), 11.1 (CH3), 
10.6 (CH3). ESI MS (1704.87): 1706.3 (M + H+). 
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5,11,17,23-Tetrakis(3-azidopropyl)-25-(ethoxycarbonylmethoxy)-26,27,28-tripropoxy-
calix[4]arene (12). 
O OO O
N3 N3
N3N3
EtO2C
 
To a stirred solution of alcohol 7 (159 mg, 0.18 mmol) in anhydrous DMF (3 mL) was added NaH 
(15 mg, 0.37 mmol, of a 60% dispersion in oil) and, after 15 min, ethyl bromoacetate (60 µL, 0.54 
mmol). The mixture was stirred at 55 °C for 18 h, then cooled to room temperature, diluted with 1 
M phosphate buffer at pH 7 (15 mL) and extracted with Et2O (2 x 50 mL). The combined organic 
phases were dried (Na2SO4) and concentrated. The residue was eluted from a column of silica gel 
with 8:1 cyclohexane-AcOEt to give 12 (144 mg, 82%) as a syrup; 1H NMR (400 MHz): δ 6.67 (s, 
2H, Ar), 6.65 (s, 2H, Ar), 6.23 (s, 4H, Ar), 4.77 (s, 2H, OCH2CO2), 4.60 and 3.12 (2d, 4H, J = 13.5 
Hz, 2 ArCH2Ar), 4.39 and 3.07 (2d, 4H, J = 13.0 Hz, 2 ArCH2Ar), 4.19 (q, 2H, J = 7.2 Hz, 
CO2CH2CH3), 3.88-3.83 (m, 2H, CH3CH2CH2O), 3.80-3.70 (m, 4H, 2 CH3CH2CH2O), 3.23 (t, 2H, 
J = 6.8 Hz, ArCH2CH2CH2), 3.22 (t, 2H, J = 6.8 Hz, ArCH2CH2CH2), 3.10 (t, 4H, J = 6.8 Hz, 2 
ArCH2CH2CH2), 2.55-2.50 (m, 4H, 2 ArCH2CH2CH2), 2.22 (t, 4H, J = 7.5 Hz, 2 ArCH2CH2CH2), 
2.01-1.78 (m, 10H, 3 CH3CH2CH2O, 2 ArCH2CH2CH2), 1.66-1.56 (m, 4H, 2 ArCH2CH2CH2), 1.30 
(t, 3H, J = 7.2 Hz, CO2CH2CH3), 1.04 (t, 6H, J = 7.5 Hz, 2 CH3CH2CH2O), 0.98 (t, 3H, J = 7.5 Hz, 
CH3CH2CH2O). 13C NMR (75 MHz): δ 170.4 (C), 155.3 (C), 154.3 (C), 135.5 (C), 135.2 (C), 134.4 
(C), 134.0 (C), 133.8 (C), 128.6 (CH), 128.3 (CH), 127.7 (CH), 127.6 (CH), 77.0 (CH2), 70.3 
(CH2), 60.2 (CH2), 50.6 (CH2), 32.0 (CH2), 31.3 (CH2), 30.8 (CH2), 30.5 (CH2), 23.2 (CH2), 14.2 
(CH3), 10.5 (CH3), 10.1 (CH3). ESI MS (969.18): 987.4 (M + NH4+). 
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5,11,17,23-Tetrakis{3-[4-(2,3,4,6-tetra-O-acetyl-β-D-galacto-pyranosyl)-1H-1,2,3-triazol-1-
yl]propyl}-25-(ethoxycarbonyl-methoxy)-26,27,28-tripropoxy-calix[4]arene (13). 
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The cycloaddition between the tetra-azide 12 (140 mg, 0.14 mmol) and the ethynyl C-galactoside 
9 (226 mg, 0.63 mmol) was carried out as described for the preparation of 10 to give, after column 
chromatography of silica gel (AcOEt), 13 (277 mg, 80%) as a white foam; [α]D = -8.6 (c 0.9, 
CHCl3). 1H NMR (400 MHz): δ 7.68 (s, 1H, H-5 Tr.), 7.66 (s, 1H, H-5 Tr.), 7.59 (s, 2H, 2 H-5 Tr.), 
6.66 (s, 2H, Ar), 6.65 (s, 2H, Ar), 6.23 (s, 2H, Ar), 6.22 (s, 2H, Ar), 5.53-5.51 (4dd, 4H, 4 H-4), 
5.44 (dd, 2H, J1,2 = J2,3 = 10.0 Hz, 2 H-2), 5.42 (dd, 2H, J1,2 = J2,3 = 10.0 Hz, 2 H-2), 5.19 (dd, 2H, 
J3,4 = 3.2 Hz, 2 H-3), 5.18 (dd, 2H, J3,4 = 3.2 Hz, 2 H-3), 4.76 (s, 2H, OCH2CO2), 4.75 (d, 2H, 2 H-
1), 4.73 (d, 2H, 2 H-1), 4.61 and 3.11 (2d, 4H, J = 13.5 Hz, 2 ArCH2Ar), 4.39 and 3.06 (2d, 4H, J = 
13.0 Hz, 2 ArCH2Ar), 4.30-4.25 (m, 4H, 2 ArCH2CH2CH2), 4.18 (q, 2H, J = 7.0 Hz, CO2CH2CH3), 
4.16-4.08 (m, 16H, 4 H-5, 8 H-6, 2 ArCH2CH2CH2), 3.87-3.86 (m, 2H, CH3CH2CH2O), 3.79-3.69 
(m, 4H, 2 CH3CH2CH2O), 2.50-2.43 (m, 4H, 2 ArCH2CH2CH2), 2.17-2.09 (m, 8H, 2 
ArCH2CH2CH2, 2 ArCH2CH2CH2), 2.16, 2.02, 2.01, 1.99, 1.90, and 1.87 (6s, 48H, 16 Ac), 1.96-
1.84 (m, 10H, 2 ArCH2CH2CH2, 3 CH3CH2CH2O), 1.27 (t, 3H, J = 7.0 Hz, CO2CH2CH3), 1.01 (t, 
6H, J = 7.5 Hz, 2 CH3CH2CH2O), 0.94 (t, 3H, J = 7.5 Hz, CH3CH2CH2O). 13C NMR (75 MHz): δ 
170.3 (C), 170.1 (C), 170.0 (C), 169.6 (C), 155.5 (C), 154.5 (C), 144.3 (C), 144.1 (C), 135.6 (C), 
135.3 (C), 133.9 (C), 133.7 (C), 133.2 (C), 128.3 (CH), 127.6 (CH), 122.1 (CH), 76.9 (CH2), 74.6 
(CH), 73.7 (CH), 71.8 (CH), 70.2 (CH2), 68.6 (CH), 67.5 (CH), 61.4 (CH2), 60.2 (CH2), 49.6 (CH2), 
31.8 (CH2), 31.3 (CH2), 30.8 (CH2), 23.1 (CH2), 20.6 (CH3), 20.5 (CH3), 14.1 (CH3), 10.4 (CH3), 
10.0 (CH3). ESI MS (2394.48): 1198.7 (M + 2H+)/2. 
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5,11,17,23-Tetrakis{3-[4-(β-D-galactopyranosyl)-1H-1,2,3-triazol-1-yl]propyl}-25-
carboxylmethoxy-26,27,28-tripropoxy-calix[4]arene (14). 
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A solution of 13 (100 mg, 0.04 mmol) in a 0.2 M solution of NaOEt in EtOH (2 mL, prepared 
from Na and EtOH immediately before the use) was kept at room temperature for 3 h in a nitrogen 
atmosphere, then neutralized with Dowex 50 X2-400 resin (H+ form, activated and washed with 
H2O and EtOH immediately before the use), and filtered through a sintered glass filter. The resin 
was washed with H2O and DMF, and the solution was concentrated. A solution of the residue in 0.2 
M aqueous NaOH (2 mL) was kept at room temperature for 24 h in a nitrogen atmosphere, then 
neutralized with Dowex 50 X2-400 resin (H+ form, activated and washed with H2O and EtOH 
immediately before the use), and filtered through a sintered glass filter. The resin was washed with 
H2O and DMF, and the solution was concentrated. The residue was eluted from a C18 silica gel 
cartridge with 1:1 H2O-CH3OH, then CH3OH, to give 14 (44 mg, 62%) as an amorphous solid; [α]D 
= +14.2 (c 0.5, DMF). 1H NMR (300 MHz, DMSO-d6 + D2O) selected data: δ 8.04 (s, 2H, 2 H-5 
Tr.), 7.96 (s, 2H, 2 H-5 Tr.), 6.76 (s, 4H, Ar), 6.50 (s, 2H, Ar), 6.47 (s, 2H, Ar), 4.60 (s, 2H, 
OCH2CO2), 4.45 and 3.14 (2d, 4H, J = 13.0 Hz, 2 ArCH2Ar), 4.31 and 3.14 (2d, 4H, J = 13.0 Hz, 2 
ArCH2Ar), 2.37-2.26 (m, 4H, 2 ArCH2CH2CH2), 2.18-2.08 (m, 4H), 2.04-1.75 (m, 14H), 0.96 (t, 
6H, J = 7.5 Hz, 2 CH3CH2CH2O), 0.93 (t, 3H, J = 7.5 Hz, CH3CH2CH2O). 13C NMR (75 MHz, 
DMSO-d6 + D2O) selected data: δ 146.9 (C), 135.5 (C), 134.7 (C), 128.5 (CH), 124.0 (CH), 80.0 
(CH), 79.9 (CH), 75.5 (CH), 70.8 (CH), 69.5 (CH), 61.4 (CH2), 49.3 (CH2), 31.9 (CH2), 23.3 (CH2), 
11.0 (CH3). ESI MS (1693.84): 1694.7 (M + H+).  
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5,11,17,23-Tetrakis{3-[4-(β-D-galactopyranosyl)-1H-1,2,3-triazol-1-yl]propyl}-25-[(11-azido-
3,6,9-trioxaundecan-1-amino)carbonyl-methoxy]-26,27,28-tripropoxy-calix[4]arene (2). 
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A mixture of 14 (21 mg, 0.012 mmol), 1-hydroxybenzotriazole hydrate (HOBT, 3 mg, 0.024 
mmol), and N-(3-dimethylaminopropyl)-N’-ethyl-carbodiimide (EDC, 14 mg, 0.072 mmol) in 
anhydrous DMF (2 mL) was stirred at room temperature for 30 min, then commercially available 
11-azido-3,6,9-trioxaundecan-1-amine 15 (10 µL, 0.036 mmol) was added. Stirring was continued 
for an additional 48 h, then the solvent was removed under vacuum. The residue was eluted from a 
C18 silica gel cartridge with H2O-CH3OH (from 1:1 to 1:5), then CH3OH, to give 2 (12 mg, 51%) 
as an amorphous solid; [α]D = +14.5 (c 0.4, CH3OH). 1H NMR (400 MHz, CD3OD): δ 8.11, 8.10, 
7.90, and 7.89 (4s, 4H, 4 H-5 Tr.), 6.94 (s, 2H, Ar), 6.91 (s, 2H, Ar), 6.30-6.26 (m, 4H, Ar), 4.82 (s, 
2H, OCH2CO2), 4.43 and 3.27 (2d, 4H, J = 13.5 Hz, 2 ArCH2Ar), 4.40 and 3.14 (2d, 4H, J = 13.0 
Hz, 2 ArCH2Ar), 4.39 (d, 2H, J1,2 = 9.8 Hz, 2 H-1), 4.34 (d, 2H, J1,2 = 9.8 Hz, 2 H-1), 4.28-4.22 (m, 
4H, 2 ArCH2CH2CH2), 4.11-4.06 (m, 4H, 2 ArCH2CH2CH2), 3.99-3.91 (8 dd, 8H, 4 H-2, 4 H-4), 
3.91-3.78 (m, 6H, 3 CH3CH2CH2O), 3.76-3.56 (m, 30H), 3.31-3.29 (m, 2H), 2.58-2.51 (m, 4H, 2 
ArCH2CH2CH2), 2.27-2.16 (m, 4H, 2 ArCH2CH2CH2), 2.05-1.97 (m, 4H, 2 ArCH2CH2CH2), 1.95-
1.72 (m, 10H, 2 ArCH2CH2CH2, 3 CH3CH2CH2O), 1.02 (t, 6H, J = 7.5 Hz, 2 CH3CH2CH2O), 0.92 
(t, 3H, J = 7.5 Hz, CH3CH2CH2O). 13C NMR (75 MHz, CD3OD): δ 173.3 (C), 157.2 (C), 156.3 (C), 
154.4 (C), 147.7 (C), 147.2 (C), 137.5 (C), 135.9 (C), 135.7 (C), 135.4 (C), 134.9 (C), 134.0 (C), 
131.1 (CH), 130.3 (CH), 129.3 (CH), 128.9 (CH), 125.1 (CH), 124.9 (CH), 80.9 (CH), 78.9 (CH2), 
77.8 (CH2), 76.3 (CH), 76.2 CH), 75.0 (CH2), 72.2 (CH), 72.0 (CH), 71.8 (CH2), 71.7 (CH2), 71.6 
(CH2), 71.2 (CH2), 71.0 (CH), 70.9 (CH2), 62.9 (CH2), 51.7 (CH2), 50.8 (CH2), 50.4 (CH2), 33.0 
(CH2), 32.5 (CH2), 32.1 (CH2), 24.2 (CH2), 24.0 (CH2), 10.8 (CH3), 10.4 (CH3). ESI MS (1894.08): 
1895.3 (M + H+).  
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Mono- (16)36 and di-alkyne (17)36 solid supports were synthesized as previously described. 
 
Synthesis of 5'-Cy3-oligonucleotides with 3'-mono- or 3'-di-alkyne functions. 
The oligonucleotides were synthesized on a DNA synthesizer (ABI 394) using standard 
phosphoramidite chemistry starting from the monoalkyne 16 or the dialkyne 17 solid supports. 
Detritylation was performed with 3% DCA in CH2Cl2 for 35 s for the dimethoxytrityl groups and 
for 60 s for the monomethoxytrityl group (Cy3). For the coupling step, benzylmercaptotetrazole 
was used as activator (0.3 M in anhydrous CH3CN), commercially available phosphoramidites (A, 
T, C, G, Cy3) (0.075 M in anhydrous CH3CN) were introduced with a 20 s coupling time. The 
capping step was performed with acetic anhydride using commercial solution (Cap A: Ac2O, 
pyridine, THF 10/10/80 and Cap B: 10% N-methylimidazole in THF) for 15 s. Oxidation was 
performed using a commercially available solution of iodine (0.1 M I2, THF-pyridine-water 90:5:5) 
for 13 s. 
 
Synthesis of 5'-Cy3-CCG CGT TGG ATT AGC (PePO galactosyl2)5 propanol (25). 
Starting from 1,3-propanediol solid support five 3-(4,4'-dimethoxytrityloxy)- 2,2-
bis(propargyloxymethyl)-propyl (2-cyanoethyl N,N-diisopropyl)-phosphoramidite11 were coupled 
according to the phosphoramidite elongation cycle (see above) and the three first nucleotides. Solid 
supported DMTr-AbzGibuCbz decaalkyne derivative (0.6 µmol) was transferred into a microwave vial 
and 1-azido-3,6-dioxaoct-8-yl 2,3,4,6-tetra-O-acetyl-β-D-galactopyranoside12. 45 (30 µmol, 15.2 mg, 
in 100 µL of methanol), CuSO4 (1.2 µmol, 6 µL of 200 mM water solution) and sodium ascorbate 
(6 µmol, 24 µL of 250 mM water solution) were added. The sealed vial was irradiated with 
microwaves for 20 min at 60 °C under magnetic stirring. After filtration, washing with methanol-
water and dry acetonitrile, and drying under dessicator, the beads were transferred into a DNA 
column and the sequence was completed on the DNA synthesizer with a Cy3 at the 5'-end. After 
deprotection and HPLC purification the pure 25 was characterized by MALDI-TOF MS; m/z 
calculated for C353H531N87O208P21 (M-H)- 9972.02, found 9971.03. 
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General procedure for deprotection. 
The beads were treated with concentrated aqueous ammonia (~1mL) at 55 °C for 6 h, then the 
supernatant was withdrawn and evaporated to dryness. The residue was dissolved in water for 
subsequent analyses. 
 
Cu(I)-catalyzed cycloaddition for mono- and di-calix[4]arene oligonucleotide conjugates (22-
23). 
To monoalkyne oligonucleotide 20 (0.5 µmol) were added 1 (4 equiv., 100 µL of a 0.02 M 
solution in water), CuSO4 (5 equiv., 2.5 µmol, 13 µL of a 0.2 M solution in H2O), freshly prepared 
sodium ascorbate (25 equiv., 12.5 µmol, 64 µL of a 0.2 M solution in H2O), and water (300 µL). 
The mixture was heated at 60 °C for 1 h in a sealed tube using a microwave synthesizer Initiator 
from Biotage (temperature monitored with an internal infrared probe). 500 µL of saturated aqueous 
EDTA solution was then added to the mixture and the resulting solution was desalted on NAP10. 
The crude product was purified on reversed-phase preparative HPLC to yield 111 nmol of pure 
compound 22, determined by spectrophotometry at 550 nm (ε(Cy3) =150000). RT (HPLC) = 15.42 
min; MALDI-TOF MS: m/z calculated for C264H345N68O124P16 (M-H)- 6950.62 found 6949.63. 
 
The synthesis of conjugate 23 (70 nmol) was performed as described above using 6 equiv. of 2. RT 
(HPLC) = 17.18 min; MALDI-TOF MS: m/z calculated for C366H490N85O157P16 (M-H)- 9087.98 
found 9090.22. 
 
Fabrication of Microarrays12 
Silanisation of the glass slides. Borosilicate glass slides (Schott) bearing 52 microreactors39 (2 mm 
diameter, 65-100 µm deep) were functionalised according to the protocol developed by Dugas et 
al.37 In brief, after piranha treatment, the slides were heated under dry nitrogen for 2 h at 150 °C. 
Next, dry pentane (250 ml) and tert-butyl-11-(dimethylamino)silylundecanoate (300 µl) were added 
at room temperature. After 20 min of incubation, pentane was evaporated and the slides were heated 
at 150 °C overnight. Functionalised slides were obtained after washing in THF and rinsing in water. 
Deprotection of the ester function was performed using formic acid (7 h at room temperature). N-
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Hydroxysuccinimide (0.1 M) and di(isopropyl)-carbodiimide (0.1 M) in dry THF were used for the 
activation of the acid functions. 
 
Immobilization of DNA strands. 3’-Amino modified oligonucleotides were purchased from 
Eurogentec. Sequence 1 S1: 5’-GTG AGC CCA GAG GCA GGG-(CH2)7-NH2, Sequence 2 S2: 5’-
GCT AAT CCA ACG CGG GCC AAT CCT T-(CH2)7-NH2 and Sequence 3 (negative control) S3: 
5'-ATG CCC TCT TTG ATA TT-(CH2)7-NH2 were used. At the bottom of the corresponding well, 
1 µl of the desired sequence (25 µM in PBS 10x (pH 8.5) were deposited. The coupling reaction 
was performed overnight at room temperature. Water was then allowed to slowly evaporate. The 
slides were washed with SDS 0.1% at 70 °C for 30 min and rinsed with deionized water. 
 
Blocking. After immobilization all slides were blocked with Bovine Serum Albumin (BSA). 
Blocking was performed with a 4% BSA solution in PBS 1x (pH 7.4), at room temperature for 2 h. 
The glass slides were then washed in PBS 1x (pH 7.4)-Tween20 0.05% 3 x 3 minutes followed by 
PBS 1x (pH 7.4) 2-3 times, rinsed with deionized water, and dried by centrifugation. 
 
Hybridization of the glycoconjugates on DNA array. Glycoconjugates bearing a DNA tag were 
hybridized with 1 µL of a solution at the desired concentrations (SSC 5x, 0.1% SDS) placed at the 
bottom of the corresponding well and allowed to hybridize overnight at room temperature in a H2O 
vapor saturated chamber. The slides were washed in SSC 2x, 0.1% SDS at 51 °C for 1 min followed 
by SSC 2x at room temperature for an additional 5 min, and then rinsed with deionized water and 
dried by centrifugation. 
 
Probing Microarrays 
Cy5 Labelling of RCA 120 lectin. RCA 120 (Sigma) was labelled with Amersham Biosciences 
Cy5 Ab Labelling Kit according to the manufacturer’s protocol. Protein concentration and the dye 
to protein ratio were estimated by optical density (nanodrop) reading the absorbance at 280 and 650 
nm. Lectin concentration was estimated to be 4 µM bearing an average of 4 dyes per protein. 
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Labelling of PA-IL lectin (gift from A. Imberty, CERMAV) with Alexa 647 was performed with 
the microscale labelling kit from Invitrogen. Protein concentration was estimated according to the 
manufacturer protocol by reading the absorbance at 280 and 650 nm. The final lectin concentration 
was estimated at 28 µM with a degree of labelling of 0.4. 
The labeled lectin was diluted in PBS 1x (pH 7.4), CaCl2 (final concentration 5 µM) and 20% BSA 
(final concentration 2%) to the desired concentration. For IC50 experiments, lactose was added into 
the solution at different final concentrations. 1 µL of each solution was placed at the bottom of each 
well and incubated at 37 °C in a H2O vapor saturated chamber for 2 h. Then the slides were washed 
in PBS1x (pH 7.4)-Tween20 0.02% for 10 min, dried by centrifugation, and scanned. 
Fluorescence scanning. Fluorescent scanning was performed using a Microarray scanner, GenePix 
4100A software package (Axon Instruments) (excitation 532/635 nm and emission 575/670 nm). 
The fluorescence signal of each conjugate was determined as the average of the mean fluorescence 
signal of four spots. 
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